OC-459
- Generic Name
- OC-459
- Drug Type
- Small Molecule
- Chemical Formula
- C21H17FN2O2
- CAS Number
- 851723-84-7
- Unique Ingredient Identifier
- 04XB9TB8OL
- Background
OC000459 is under investigation for the treatment of Severe Eosinophilic Asthma. OC000459 has been investigated for the treatment of Bronchial Asthma.
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
- Conditions
- Picornaviridae InfectionsAsthmaCommon ColdRhinovirus
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 44
- Registration Number
- NCT02660489
- Locations
- ๐ฌ๐ง
St Mary's Hospital, London, Greater London, United Kingdom
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 40
- Registration Number
- NCT02560610
- Locations
- ๐ฌ๐ง
University of Oxford, Oxford, Oxfordshire, United Kingdom
Evaluation of Metabolic Profile of OC000459
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Atopix Therapeutics, Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT02341521
- Locations
- ๐ฌ๐ง
Simbec Research, Merthyr Tydfil, Wales, United Kingdom
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Atopix Therapeutics, Ltd.
- Target Recruit Count
- 142
- Registration Number
- NCT02002208
- Locations
- ๐ฌ๐ง
University of Sheffield, Sheffield, United Kingdom
A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2011-10-07
- Lead Sponsor
- Oxagen Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT01448902
- Locations
- ๐ฆ๐น
Vienna Challenge Chamber, Vienna, Austria
Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2010-01-28
- Lead Sponsor
- Oxagen Ltd
- Target Recruit Count
- 132
- Registration Number
- NCT01057927
- Locations
- ๐ท๐บ
City Hospital #7, Moscow, Russian Federation
๐ท๐บSverdlovsk Regional Hospital #1, Ekaterinburg, Russian Federation
๐ท๐บResearch Institute of Pulmonology, Moscow, Russian Federation
Proof of Concept Study of OC000459 in Eosinophilic Esophagitis
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Oxagen Ltd
- Target Recruit Count
- 26
- Registration Number
- NCT01056783
- Locations
- ๐จ๐ญ
Swiss EoE Research Group, Olten, Switzerland
OC000459 Bronchial Allergen Challenge
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- Oxagen Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT01056692
- Locations
- ๐ฌ๐ง
King's College London School of Medicine, London, United Kingdom
๐ฌ๐งMedicines Evaluation Unit, Manchester, United Kingdom
Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2010-09-02
- Lead Sponsor
- Oxagen Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT01056575
- Locations
- ๐ฌ๐ง
Simbec Research Ltd, Merthyr Tydfil, United Kingdom
OC000459 Dose Finding Study in Hay Fever Sufferers.
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Oxagen Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT00697281
- Locations
- ๐ฆ๐น
Allergie Zentrum Wien West, Vienna Challenge Chamber, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.